Rapid Dose Therapeutics Corp.
DOSE
CNSX
| 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.18M | 984.20K | 872.50K | 757.20K | 774.90K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.18M | 984.20K | 872.50K | 757.20K | 774.90K |
| Cost of Revenue | 475.20K | 383.50K | 328.30K | 314.70K | 400.70K |
| Gross Profit | 702.40K | 600.70K | 544.20K | 442.50K | 374.20K |
| SG&A Expenses | 3.06M | 2.69M | 2.30M | 1.82M | 1.85M |
| Depreciation & Amortization | 286.70K | 363.60K | 432.10K | 479.40K | 535.80K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.12M | 3.77M | 3.39M | 2.93M | 2.93M |
| Operating Income | -2.95M | -2.79M | -2.51M | -2.17M | -2.15M |
| Income Before Tax | -4.25M | -3.97M | -3.72M | -3.21M | -2.65M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.25 | -3.97 | -3.72 | -3.21 | -2.65 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.25M | -3.97M | -3.72M | -3.21M | -2.65M |
| EBIT | -2.95M | -2.79M | -2.51M | -2.17M | -2.15M |
| EBITDA | -2.75M | -2.52M | -2.17M | -1.77M | -1.67M |
| EPS Basic | -0.04 | -0.04 | -0.03 | -0.03 | -0.03 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| EPS Diluted | -0.04 | -0.04 | -0.03 | -0.03 | -0.03 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| Average Basic Shares Outstanding | 477.25M | 456.43M | 436.89M | 418.54M | 413.94M |
| Average Diluted Shares Outstanding | 477.25M | 456.43M | 436.89M | 418.54M | 413.94M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
